These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17117721)

  • 1. Exploratory IND: a new regulatory strategy for early clinical drug development in the United States.
    Sarapa N
    Ernst Schering Res Found Workshop; 2007; (59):151-63. PubMed ID: 17117721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
    Schwarz SW; Oyama R
    J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
    Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
    J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 0 clinical trials: conceptions and misconceptions.
    Kummar S; Rubinstein L; Kinders R; Parchment RE; Gutierrez ME; Murgo AJ; Ji J; Mroczkowski B; Pickeral OK; Simpson M; Hollingshead M; Yang SX; Helman L; Wiltrout R; Collins J; Tomaszewski JE; Doroshow JH
    Cancer J; 2008; 14(3):133-7. PubMed ID: 18536551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leveraging exploratory investigational new drug studies to accelerate drug development.
    Jacobson-Kram D; Mills G
    Clin Cancer Res; 2008 Jun; 14(12):3670-4. PubMed ID: 18559581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
    Senderowicz AM
    Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of research: is it a drug trial or a supplement trial?
    Chen ST
    Fitoterapia; 2011 Jan; 82(1):14-6. PubMed ID: 21073930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.
    Black LE; Farrelly JG; Cavagnaro JA; Ahn CH; DeGeorge JJ; Taylor AS; DeFelice AF; Jordan A
    Antisense Res Dev; 1994; 4(4):299-301. PubMed ID: 7734946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
    Marchetti S; Schellens JH
    Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Apr; 73(82):22800-16. PubMed ID: 18567164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation; draft guidance on E2F Development Safety Update Report; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(151):45462-3. PubMed ID: 18949880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.